Dadachanji Group Launches Kaisha Pharma with €45 Million Investment in Pharmaceutical Glass Packaging Manufacturing
The Dadachanji Group has launched Kaisha Pharma with an initial investment of 45 million, marking its return to the pharmaceutical glass-packaging segment. The venture targets Indian and global pharmaceutical and biotechnology companies.
Kaisha Pharma will manufacture primary pharmaceutical packaging products, including ampoules, vials, prefilled syringes and cartridges, along with ready-to-use (RTU) platforms for vials, syringes and cartridges. The company is also developing specialty containment solutions for biologics, advanced therapeutics and sensitive drug formulations.
The company is setting up a manufacturing complex spread over more than 300,000 square feet, equipped with integrated production lines, camera-based inspection systems, and analytical and testing laboratories.
Kaisha Pharma is also setting up an international business development office in Europe to serve as a hub for customer engagement, technical collaboration and market development in the region. The Dadachanji Group said the 45-million deployment forms part of a larger multi-million-euro investment commitment toward expanding infrastructure, manufacturing capacity and operational capabilities.